|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes
From the Diabetes Prevention Program Coordinating Center, Biostatistics Center, Rockville, Maryland
Address correspondence and reprint requests to the Diabetes Prevention Program Group, Diabetes Prevention Program Coordinating Center, George Washington University Biostatistics Center, 6110 Executive Blvd., Suite 750, Rockville, MD 20852. E-mail: dppmail{at}biostat.bsc.gwu.edu
OBJECTIVE—The Diabetes Prevention Program (DPP) demonstrated that intensive lifestyle and metformin interventions reduced the incidence of type 2 diabetes compared with a placebo intervention. The aim of this study was to assess the cost-effectiveness of the lifestyle and metformin interventions relative to the placebo intervention.
RESEARCH DESIGN AND METHODS—Analyses were performed from a health system perspective that considered direct medical costs only and a societal perspective that considered direct medical costs, direct nonmedical costs, and indirect costs. Analyses were performed with the interventions as implemented in the DPP and as they might be implemented in clinical practice.
RESULTS—The lifestyle and metformin interventions required more resources than the placebo intervention from a health system perspective, and over 3 years they cost approximately $2,250 more per participant. As implemented in the DPP and from a societal perspective, the lifestyle and metformin interventions cost $24,400 and $34,500, respectively, per case of diabetes delayed or prevented and $51,600 and $99,200 per quality-adjusted life-year (QALY) gained. As the interventions might be implemented in routine clinical practice and from a societal perspective, the lifestyle and metformin interventions cost $13,200 and $14,300, respectively, per case of diabetes delayed or prevented and $27,100 and $35,000 per QALY gained. From a health system perspective, costs per case of diabetes delayed or prevented and costs per QALY gained tended to be lower.
CONCLUSIONS—Over 3 years, the lifestyle and metformin interventions were effective and were cost-effective from the perspective of a health system and society. Both interventions are likely to be affordable in routine clinical practice, especially if implemented in a group format and with generic medication pricing.
Abbreviations: DPP, Diabetes Prevention Program • IGT, impaired glucose tolerance • NNT, number needed to treat • QALY, quality-adjusted life-year • QWB-SA, Self-Administered Quality of Well-Being Index
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T. J. Hoerger, K. A. Hicks, S. W. Sorensen, W. H. Herman, R. E. Ratner, R. T. Ackermann, P. Zhang, and M. M. Engelgau Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults Diabetes Care, November 1, 2007; 30(11): 2874 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ramachandran, C. Snehalatha, A. Yamuna, S. Mary, and Z. Ping Cost-Effectiveness of the Interventions in the Primary Prevention of Diabetes Among Asian Indians: Within-trial results of the Indian Diabetes Prevention Programme (IDPP) Diabetes Care, October 1, 2007; 30(10): 2548 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman Diabetes Epidemiology: Guiding Clinical and Public Health Practice: The Kelly West Award Lecture, 2006 Diabetes Care, July 1, 2007; 30(7): 1912 - 1919. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gordon, N. Graves, A. Hawkes, and E. Eakin A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol Chronic Illness, June 1, 2007; 3(2): 101 - 129. [Abstract] [PDF]
|
|
|
|
|
|
M. A.M. Jacobs-van der Bruggen, G. Bos, W. J. Bemelmans, R. T. Hoogenveen, S. M. Vijgen, and C. A. Baan Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk: Results from a modeling study Diabetes Care, January 1, 2007; 30(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Hagberg and L. Lindholm Review Article: Cost-effectiveness of healthcare-based interventions aimed at improving physical activity Scand J Public Health, December 1, 2006; 34(6): 641 - 653. [Abstract] [PDF]
|
|
|
|
|
|
R. T. Ackermann, D. G. Marrero, K. A. Hicks, T. J. Hoerger, S. Sorensen, P. Zhang, M. M. Engelgau, R. E. Ratner, and W. H. Herman An Evaluation of Cost Sharing to Finance a Diet and Physical Activity Intervention to Prevent Diabetes. Diabetes Care, June 1, 2006; 29(6): 1237 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Johnson, R. Manjunath, C. A. Mansfield, L. J. Clayton, T. J. Hoerger, and P. Zhang High-Risk Individuals' Willingness to Pay for Diabetes Risk-Reduction Programs. Diabetes Care, June 1, 2006; 29(6): 1351 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. B. Lin, W. Katon, C. Rutter, G. E. Simon, E. J. Ludman, M. Von Korff, B. Young, M. Oliver, P. C. Ciechanowski, L. Kinder, et al. Effects of Enhanced Depression Treatment on Diabetes Self-Care Ann. Fam. Med, January 1, 2006; 4(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Brown III, J. K. Estrada, G. Hazarika, and E. Bastida Diabetes and the Labor Market: The community-wide economic cost in the Lower Rio Grande Valley Diabetes Care, December 1, 2005; 28(12): 2945 - 2947. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Eddy, L. Schlessinger, and R. Kahn Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes Ann Intern Med, August 16, 2005; 143(4): 251 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Brown, S. A. Blozis, K. Kouzekanani, A. A. Garcia, M. Winchell, and C. L. Hanis Dosage Effects of Diabetes Self-Management Education for Mexican Americans: The Starr County Border Health Initiative Diabetes Care, March 1, 2005; 28(3): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Padwal, S. R. Majumdar, J. A. Johnson, J. Varney, and F. A. McAlister A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 736 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Herman, T. J. Hoerger, M. Brandle, K. Hicks, S. Sorensen, P. Zhang, R. F. Hamman, R. T. Ackermann, M. M. Engelgau, R. E. Ratner, et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance Ann Intern Med, March 1, 2005; 142(5): 323 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhang, M. M. Engelgau, S. L. Norris, E. W. Gregg, and K. M. Venkat Narayan Application of Economic Analysis to Diabetes and Diabetes Care Ann Intern Med, June 1, 2004; 140(11): 972 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted: 14 Nov 2003 to 30 Jan 2004 Evid. Based Nurs., April 1, 2004; 7(2): e2 - e2. [Full Text] [PDF]
|
|
|
|
|
|
S. Teutsch The Cost-Effectiveness of Preventing Diabetes Diabetes Care, September 1, 2003; 26(9): 2693 - 2694. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |